Biomarkers for Hepatobiliary Cancers

被引：154

作者：

Nault, Jean-Charles ^{[1
,2
,3
]}

Villanueva, Augusto ^{[4
,5
]}

机构：

[1] Univ Paris 13, Funct Genom Solid Tumors Lab, Ctr Rech Cordeliers, Sorbonne Univ,Inserm,USPC,Univ Paris Descartes,Un, Paris, France

[2] Hop Univ Paris Seine St Denis, AP HP, Hop Jean Verdier, Liver Unit, Bondy, France

[3] Univ Paris 13, Unite Format & Rech Sante Med & Biol Humaine, Paris, France

[4] Icahn Sch Med Mt Sinai, Liver Canc Program, Tisch Canc Inst, Div Liver Dis,Dept Med, 1425 Madison Ave,Box 1123,Room 11-70E, New York, NY 10029 USA

[5] Icahn Sch Med Mt Sinai, Dept Med, Div Hematol & Med Oncol, New York, NY 10029 USA

来源：

HEPATOLOGY | 2021年 / 73卷

关键词：

ADVANCED HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; EXTRACELLULAR VESICLES; THERAPEUTIC TARGETS; DOUBLE-BLIND; PHASE-II; CHOLANGIOCARCINOMA; PROGNOSIS; MUTATIONS; SUBTYPES;

D O I：

10.1002/hep.31175

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The clinical management of primary liver cancers such as hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) has significantly changed in the last 3 years. The introduction of systemic therapies, including immune-based therapies and biomarker-driven therapies, has significantly improved survival, particularly in patients at advanced stages of disease. Survival is still poor, and projections from the World Health Organization underscore the need to improve outcomes in these patients. Biomarkers have emerged as powerful tools for the diagnosis, prognosis, and prediction of treatment responses to improve patient stratification and maximize clinical benefits. Recent advances in understanding the molecular alterations of HCC have not yet translated into biomarkers. Some reasons for the lack of progress are the absence of druggable mutations in the majority of liver cancers and the significant heterogeneity of the disease. In contrast, several therapeutic targets have been identified in CCA, and biomarker-driven therapies are currently under evaluation in phase 2/3 clinical trials. Here, we summarize the status on biomarker development for HCC and CCA.

引用

页码：115 / 127

页数：13

共 98 条

[1] Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis [J].

Albiin, N. ;

Smith, I. C. P. ;

Arnelo, U. ;

Lindberg, B. ;

Bergquist, A. ;

Dolenko, B. ;

Bryksina, N. ;

Bezabeh, T. .

ACTA RADIOLOGICA, 2008, 49 (08) :855-862

[2] Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma [J].

Ally, Adrian ;

Balasundaram, Miruna ;

Carlsen, Rebecca ;

Chuah, Eric ;

Clarke, Amanda ;

Dhalla, Noreen ;

Holt, Robert A. ;

Jones, Steven J. M. ;

Lee, Darlene ;

Ma, Yussanne ;

Marra, Marco A. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Andrew J. ;

Schein, Jacqueline E. ;

Sipahimalani, Payal ;

Tam, Angela ;

Thiessen, Nina ;

Cheung, Dorothy ;

Wong, Tina ;

Brooks, Denise ;

Robertson, A. Gordon ;

Bowlby, Reanne ;

Mungall, Karen ;

Sadeghi, Sara ;

Xi, Liu ;

Covington, Kyle ;

Shinbrot, Eve ;

Wheeler, David A. ;

Gibbs, Richard A. ;

Donehower, Lawrence A. ;

Wang, Linghua ;

Bowen, Jay ;

Gastier-Foster, Julie M. ;

Gerken, Mark ;

Helsel, Carmen ;

Leraas, Kristen M. ;

Lichtenberg, Tara M. ;

Ramirez, Nilsa C. ;

Wise, Lisa ;

Zmuda, Erik ;

Gabriel, Stacey B. ;

Meyerson, Matthew ;

Cibulskis, Carrie ;

Murray, Bradley A. ;

Shih, Juliann ;

Beroukhim, Rameen ;

Cherniack, Andrew D. ;

Schumacher, Steven E. ;

Saksena, Gordon .

CELL, 2017, 169 (07) :1327-+

[3] Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors [J].

Andersen, Jesper B. ;

Spee, Bart ;

Blechacz, Boris R. ;

Avital, Itzhak ;

Komuta, Mina ;

Barbour, Andrew ;

Conner, Elizabeth A. ;

Gillen, Matthew C. ;

Roskams, Tania ;

Roberts, Lewis R. ;

Factor, Valentina M. ;

Thorgeirsson, Snorri S. .

GASTROENTEROLOGY, 2012, 142 (04) :1021-U552

[4]

[Anonymous], J CLIN ONCOL S

[5] Serum Extracellular Vesicles Contain Protein Biomarkers for Primary Sclerosing Cholangitis and Cholangiocarcinoma [J].

Arbelaiz, Ander ;

Azkargorta, Mikel ;

Krawczyk, Marcin ;

Santos-Laso, Alvaro ;

Lapitz, Ainhoa ;

Perugorria, Maria J. ;

Erice, Oihane ;

Gonzalez, Esperanza ;

Jimenez-Aguero, Raul ;

Lacasta, Adelaida ;

Ibarra, Cesar ;

Sanchez-Campos, Alberto ;

Jimeno, Juan P. ;

Lammert, Frank ;

Milkiewicz, Piotr ;

Marzioni, Marco ;

Macias, Rocio I. R. ;

Marin, Jose J. G. ;

Patel, Tushar ;

Gores, Gregory J. ;

Martinez, Ibon ;

Elortza, Felix ;

Falcon-Perez, Juan M. ;

Bujanda, Luis ;

Banales, Jesus M. .

HEPATOLOGY, 2017, 66 (04) :1125-1143

[6] Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis [J].

Banales, Jesus M. ;

Inarrairaegui, Mercedes ;

Arbelaiz, Ander ;

Milkiewicz, Piotr ;

Muntane, Jordi ;

Munoz-Bellvis, Luis ;

La Casta, Adelaida ;

Gonzalez, Luis M. ;

Arretxe, Enara ;

Alonso, Cristina ;

Martinez-Arranz, Ibon ;

Lapitz, Ainhoa ;

Santos-Laso, Alvaro ;

Avila, Matias A. ;

Martinez-Chantar, Maria L. ;

Bujanda, Luis ;

Marin, Jose J. G. ;

Sangro, Bruno ;

Macias, Rocio I. R. .

HEPATOLOGY, 2019, 70 (02) :547-562

[7] Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions [J].

Bolondi, Luigi ;

Burroughs, Andrew ;

Dufour, Jean-Francois ;

Galle, Peter R. ;

Mazzaferro, Vincenzo ;

Piscaglia, Fabio ;

Raoul, Jean Luc ;

Sangro, Bruno .

SEMINARS IN LIVER DISEASE, 2012, 32 (04) :348-359

[8] Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma [J].

Borad, Mitesh J. ;

Champion, Mia D. ;

Egan, Jan B. ;

Liang, Winnie S. ;

Fonseca, Rafael ;

Bryce, Alan H. ;

McCullough, Ann E. ;

Barrett, Michael T. ;

Hunt, Katherine ;

Patel, Maitray D. ;

Young, Scott W. ;

Collins, Joseph M. ;

Silva, Alvin C. ;

Condjella, Rachel M. ;

Block, Matthew ;

McWilliams, Robert R. ;

Lazaridis, Konstantinos N. ;

Klee, Eric W. ;

Bible, Keith C. ;

Harris, Pamela ;

Oliver, Gavin R. ;

Bhavsar, Jaysheel D. ;

Nair, Asha A. ;

Middha, Sumit ;

Asmann, Yan ;

Kocher, Jean-Pierre ;

Schahl, Kimberly ;

Kipp, Benjamin R. ;

Fritcher, Emily G. Barr ;

Baker, Angela ;

Aldrich, Jessica ;

Kurdoglu, Ahmet ;

Izatt, Tyler ;

Christoforides, Alexis ;

Cherni, Irene ;

Nasser, Sara ;

Reiman, Rebecca ;

Phillips, Lori ;

McDonald, Jackie ;

Adkins, Jonathan ;

Mastrian, Stephen D. ;

Placek, Pamela ;

Watanabe, Aprill T. ;

LoBello, Janine ;

Han, Haiyong ;

Von Hoff, Daniel ;

Craig, David W. ;

Stewart, A. Keith ;

Carpten, John D. .

PLOS GENETICS, 2014, 10 (02)

[9] Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma [J].

Borger, Darrell R. ;

Goyal, Lipika ;

Yau, Thomas ;

Poon, Ronnie T. ;

Ancukiewicz, Marek ;

Deshpande, Vikram ;

Christiani, David C. ;

Liebman, Hannah M. ;

Yang, Hua ;

Kim, Hyeryun ;

Yen, Katharine ;

Faris, Jason E. ;

Iafrate, A. John ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Allen, Jill N. ;

Blaszkowsky, Lawrence S. ;

Murphy, Janet E. ;

Saha, Supriya K. ;

Hong, Theodore S. ;

Wo, Jennifer Y. ;

Ferrone, Cristina R. ;

Tanabe, Kenneth K. ;

Bardeesy, Nabeel ;

Straley, Kimberly S. ;

Agresta, Sam ;

Schenkein, David P. ;

Ellisen, Leif W. ;

Ryan, David P. ;

Zhu, Andrew X. .

CLINICAL CANCER RESEARCH, 2014, 20 (07) :1884-1890

[10] Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets [J].

Boyault, Sandrine ;

Rickman, David S. ;

de Reynies, Aurelien ;

Balabaud, Charles ;

Rebouissou, Sandra ;

Jeannot, Emmanuelle ;

Herault, Aurelie ;

Saric, Jean ;

Belghiti, Jacques ;

Franco, Dominique ;

Bioulac-Sage, Paulette ;

Laurent-Puig, Pierre ;

Zucman-Rossi, Jessica .

HEPATOLOGY, 2007, 45 (01) :42-52

← 1 2 3 4 5 6 7 8 9 10 →